Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -4 of 4 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 4/25/2008 First Published: 2/17/2006


1.		Phase II Study of Recombinant LMB-2 Immunotoxin and Peptide Vaccination Comprising gp100:209-217 (210M) Antigen, MART-1:27-35 Antigen, and Montanide ISA-51 in Patients With Progressive Unresectable Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-06-C-0041 7542, NCI-7542, NCI-P6702, NCT00295958

Last Modified: 12/20/2007


2.		Phase I Study of the Recombinant Immunotoxin LMB-2 in Patients With Tac-Expressing Leukemias and Lymphomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				NCI-96-C-0064F NCI-T95-0042N, T95-0042, NCT00002765

Last Modified: 5/31/2007 First Published: 5/28/2004


3.		Phase I Study of LMB-2 Immunotoxin in Pediatric Patients With CD25-Positive Relapsed or Refractory Leukemia or Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				6 months to 21 years				NCI				NCI-04-C-0168 NCI-5903, 5903, NCT00085150

Last Modified: 6/9/2008 First Published: 10/14/2006


4.		Pilot Study of Fludarabine Phosphate and Cyclophosphamide Followed By LMB-2 Immunotoxin in Patients With CD25-Positive Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Biomarker/Laboratory analysis, Treatment				Completed				18 and over				NCI				NCI-06-C-0240 NCI-P6761, 7835, NCI-7835, NCT00389506

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute